pioneer 6 oral semaglutide cardiovascular outcomes pioneer 6 results and in Patients with Type 2 Diabetes Cardiovascular Outcomes, Safety, and Tolerability

Also, new information on treatments, dosage, and side effects.

After a two-year-long shortage, the FDA announced that Eli Lillys GLP-1 drug Mounjaro, and obesity version Zepbound, are back in stock.

Of these, 19 reports were fatal and 24 were reported as necrotising pancreatitis

Understanding the difference between appetite-suppressing drug classes helps patients and providers choose the most appropriate treatment based on individual physiology, comorbidities, and clinical response patterns

Petrelintide, a long-acting amylin analog, is being tested in Phase II trials and may offer improved tolerability and sustained weight loss.

The difference appeared to reflect less frequent drinking rather than fewer drinks per occasion or fewer binge-drinking episodes.